Related Experiment Videos
Studies on the antiviral activity of propagermanium with immunostimulating action
Y Ishiwata1, E Suzuki, S Yokochi
1Mie Laboratory, Sanwa Kagaku Kenkyusho Co., Ltd., Japan.
Abstract:
The effects of propagermanium (3-oxygermylpropionic acid polymer) on various virus-infected mice were investigated. Propagermanium did not inhibit the multiplication of various DNA or RNA viruses in vitro. Oral administration of propagermanium in mice infected with herpes simplex virus type I (HSV-1) significantly prolonged the mean survival days. The efficacy of propagermanium at doses of 1 and 10 mg/kg daily was 13.4 +/- 2.3 and 14.2 +/- 2.3 mean survival days in comparison with 7.7 +/- 0.5 mean survival days at control group. In vaccinia virus-infected mice, oral doses of propagermanium ranging from 0.2 to 10 mg/kg suppressed the number of pocks on the tail which induced by the virus. Propagermanium (0.5-10 mg/kg) orally given to HSV-1-infected mice induced cytotoxic T lymphocytes (CTL) against HSV-1 antigen. In addition, propagermanium (1-10 mg/kg) enhanced interferon-gamma (IFN-gamma) induction in mice treated with Mycobacterium bovis (BCG). In mice spleen cells cultured with Concanavalin A, 0.1 to 10 micrograms/ml of propagermanium stimulated interleukin 2 (IL-2) production. It seems likely that the antiviral activity of propagermanium was exerted via enhancement of host immune resistance against viral infection.
Insights
Propagermanium enhances host immune resistance against viral infections, significantly prolonging survival in mice infected with herpes simplex virus type I and suppressing vaccinia virus. This antiviral effect is linked to immune system modulation.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Propagermanium (3-oxygermylpropionic acid polymer) is investigated for its biological effects.
- Understanding its in vivo antiviral mechanisms is crucial for therapeutic development.
Purpose of the Study:
- To evaluate the antiviral activity of propagermanium in vivo.
- To elucidate the immunomodulatory mechanisms underlying propagermanium's antiviral effects.
Main Methods:
- Mice infected with herpes simplex virus type I (HSV-1) or vaccinia virus were treated with propagermanium.
- Immune responses including cytotoxic T lymphocyte (CTL) induction, interferon-gamma (IFN-gamma), and interleukin-2 (IL-2) production were assessed.
Main Results:
- Propagermanium significantly prolonged survival in HSV-1 infected mice and reduced vaccinia virus pocks.
- Oral administration of propagermanium induced CTLs against HSV-1.
- Propagermanium enhanced IFN-gamma induction and stimulated IL-2 production in immune cells.
Conclusions:
- Propagermanium exhibits in vivo antiviral activity against HSV-1 and vaccinia virus.
- The antiviral effects of propagermanium appear to be mediated by enhancing host immune resistance.
- Propagermanium demonstrates potential as an antiviral agent through immune system modulation.